21 May 2020 - - US-based medical technology company Eko has launched the Eko Telehealth platform for virtual cardiac and pulmonary monitoring, the company said.

Being used by more than 200 health systems TODAY, Eko Telehealth incorporates stethoscope and ECG live-streaming combined with embedded video conferencing and FDA-cleared AI algorithms for heart murmur and AFib detection.

Eko Telehealth offers AI-powered and FDA-cleared identification of heart murmurs and atrial fibrillation, assisting providers in the detection and monitoring of heart disease during virtual visits; lung and heart sound live-streaming for a thorough virtual examination; single-lead ECG live-streaming, enabling providers to assess for rhythm abnormalities; and embedded HIPAA-compliant video conferencing, or can work alongside the video conferencing platform a health system has in place.

Symptoms of valvular heart disease and AFib often go undiagnosed during routine physical exams.

With the development of Eko's AI screening algorithms, clinicians are able to harness machine learning to detect heart disease at the earliest point of care regardless if the patient visit is in-person or remote.

With Eko, a provider at a patient site, such as a hospital, rural clinic or nursing home can stream stethoscope audio and ECG to a physician residing in a separate room or at a virtual care center, medical center or specialty clinic, thus reducing in-person exposure to infectious diseases, like COVID-19.

The Eko DUO is the first combined digital stethoscope and 1-lead ECG device designed specifically for patients to operate at home, under the supervision of a healthcare provider.

For COVID-19 cases being monitored remotely, Eko helps providers assess worsening symptoms while reducing the need for patients to travel to a medical site and risk exposure or continued spread of COVID-19.

Eko is elevating the way clinicians detect and monitor cardiac and respiratory disease by bringing together advanced sensors, patient and provider software, and AI-powered analysis.

Its FDA cleared platform is used by tens of thousands of clinicians treating ms of patients around the world, in-person, and through telehealth.

The company is headquartered in Oakland, California and privately-held, with investments from ARTIS Ventures, NTT Venture Capital, DigiTx Ventures, Mayo Clinic, Sutter Health and others.